Longitudinal 4.0 Tesla 31P magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia

Psychiatry Research - Neuroimaging

Volumn 173, Issue 2, 2009, Pages 155-157

  Miller, Jodi ^a,b   Williamson, Peter ^b   Jensen, J Eric ^c   Manchanda, Rahul ^b   Menon, Ravi ^b,d   Neufeld, Richard ^b   Rajakumar, Nagalingam ^b   Pavlosky, William ^b   Densmore, Maria ^b   Schaefer, Betsy ^b   Drost, Dick J ^a,b  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c MCLEAN HOSPITAL   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Chemical shift imaging; Membrane metabolites; Neurodegeneration

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; PHOSPHORUS 31;

ANATOMICAL VARIATION; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MALE; METABOLITE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARANOID SCHIZOPHRENIA; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; SCHIZOPHRENIA; THALAMUS; VOLUMETRY;

ADULT; CASE-CONTROL STUDIES; FEMALE; FUNCTIONAL LATERALITY; GLYCERYLPHOSPHORYLCHOLINE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHATIDYLETHANOLAMINES; PHOSPHORUS; SCHIZOPHRENIA; THALAMUS; TIME FACTORS;

EID: 67651097644     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2008.10.001     Document Type: Article

References (20)

1. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) (1984), The University of Iowa, Iowa City, Iowa
2. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) (1984), The University of Iowa, Iowa City, Iowa
3. Bryden P. Measuring handedness with questionnaires. Neuropsychologia 15 (1977) 617-624
4. DeLisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophrenia Bulletin 34 (2008) 312-321
5. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders: SCID-I (1997), American Psychiatric Publishing, Inc., New York
6. Glantz L.A., Gilmore J.H., Lieberman J.A., and Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research 81 (2006) 47-63
7. 31P-MRS study at 4.0 Tesla. British Journal of Psychiatry 180 (2002) 39-44
8. 31P-MRS: measuring the phospholipid resonances at 4 Tesla from small voxels. NMR in Biomedicine 15 (2002) 338-347
9. Jensen J.E., Miller J., Williamson P.C., Neufeld R.W., Menon R.S., Malla A., Manchanda R., Schaefer B., Densmore M., and Drost D.J. Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: 31P-MRS chemical shift imaging study at 4 Tesla. British Journal of Psychiatry 184 (2004) 409-415
10. 31P spectroscopic imaging with improved sensitivity, resolution and sidelobe suppression. Journal of Magnetic Resonance, Series B 104 (1994) 85-88
11. 31P spectroscopy study. Psychiatry Research: Neuroimaging 148 (2006) 217-221
12. Steen R.G., Mull C., McClure R., Hamer R.M., and Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry 188 (2006) 510-518
13. Stevens J. Applied Multivariate Statistics for the Social Sciences. (3rd ed.) (1996), Lawrence Erlbaum Associates, Hillsdale, New Jersey
14. Théberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., and Williamson P.C. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. American Journal of Psychiatry 159 (2002) 1944-1946
15. Théberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., and Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. American Journal of Psychiatry 160 (2003) 2231-2233
16. Théberge J., Williamson K.E., Aoyama N., Drost D.J., Manchanda R., Malla A.K., Northcott S., Menon R.S., Neufeld R.W.J., Rajakumar N., Pavlosky W., Densmore M., Schaefer B., and Williamson P.C. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. The British Journal of Psychiatry 191 (2007) 325-334
17. Weinberger D.R., and McClure R.K. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?. Archives of General Psychiatry 59 (2002) 553-558
18. Williamson P. Mind, Brain, and Schizophrenia (2006), Oxford University Press, New York 118-119
19. Vance D.E. Phospholipid metabolism and cell signaling in eukaryotes. In: Vance D.E., and Vance J.E. (Eds). Biochemistry of Lipids, Lipoproteins and Membranes (2008), Elsevier, Boston 507-531
20. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64 (2003) 663-667